CC Stock Analysis: Chemours | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 2.063m USD | 12M Return: -8.9% | US1638511089 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.8M
EPS Trend: -93.3%
Qual. Beats: 0
Rev. Trend: -69.3%
Qual. Beats: -2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Chemours Co (NYSE: CC) is a U.S.-based specialty chemicals producer incorporated in 2014 and headquartered in Wilmington, Delaware. The company was spun off from DuPont in 2015 and operates across North America, Asia Pacific, Europe, the Middle East, Africa, and Latin America.
The business is organized into three reporting segments. Thermal & Specialized Solutions supplies refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents under the Freon and Opteon brands. Titanium Technologies produces TiO2 white pigment under the Ti-Pure brand for architectural and industrial coatings, plastic packaging, PVC, laminate papers, and coated paperboard. Advanced Performance Materials provides specialty solutions, membranes, industrial resins, additives, films, and coatings serving consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical markets under the Teflon, Viton, Krytox, and Nafion brands.
Chemours distributes its products through direct and indirect channels, supplemented by a network of resellers, third-party sales agents, and distributors. Classified within the Materials sector under the Diversified Chemicals sub-industry, the company sells into multiple industrial and consumer end markets, making revenue exposure sensitive to global manufacturing, construction, packaging, and electronics demand cycles.
- HFC phase-down drives Opteon refrigerant demand growth
- TiO2 pigment pricing pressured by weak coatings demand
- PFAS litigation costs weigh on cash flow outlook
| Net Income: -304.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 2.47 > 1.0 |
| NWC/Revenue: 21.27% < 20% (prev 21.27%; Δ 0.00% < -1%) |
| CFO/TA 0.05 > 3% & CFO 353.0m > Net Income -304.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (151.4m) vs 12m ago 0.76% < -2% |
| Gross Margin: 15.34% > 18% (prev 18.25%; Δ -2.92% > 0.5%) |
| Asset Turnover: 79.20% > 50% (prev 78.50%; Δ 0.71% > 0%) |
| Interest Coverage Ratio: -1.48 > 6 (EBIT TTM -404.0m / Interest Expense TTM 273.0m) |
| A: 0.17 (Total Current Assets 3.09b - Total Current Liabilities 1.86b) / Total Assets 7.15b |
| B: 0.12 (Retained Earnings 891.0m / Total Assets 7.15b) |
| C: -0.06 (EBIT TTM -404.0m / Avg Total Assets 7.32b) |
| D: -0.01 (Book Value of Equity -49.0m / Total Liabilities 7.20b) |
| Altman-Z'' = 1.16 = BB |
| DSRI: 0.96 (Receivables 907.0m/959.0m, Revenue 5.80b/5.88b) |
| GMI: 1.19 (GM 18.25% / 15.34%) |
| AQI: 0.81 (AQ_t 0.11 / AQ_t-1 0.13) |
| SGI: 0.99 (Revenue 5.80b / 5.88b) |
| TATA: -0.09 (NI -304.0m - CFO 353.0m) / TA 7.15b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of October 07, 2026, the stock is trading at USD 14.08 with a total of 1,970,621 shares traded. Over the past week, the price has changed by +1.37%, over one month by -8.87%, over three months by -22.15% and over the past year by -8.94%.
Current recommended Stop Loss: 13.30 (which is 5.5% or 1.4 ATR below the current price).
Chemours has received a consensus analysts rating of 3.78. Therefore, it is recommended to hold CC.
- StrongBuy: 3
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.6 | 31.8% |
P/E Forward = 7.3099
P/S = 0.3559
P/B = 12.5408
P/EG = 1.6042
Revenue TTM = 5.80b USD
EBIT TTM = -404.0m USD
EBITDA TTM = -85.0m USD
Long Term Debt = 3.84b USD (from longTermDebt, last quarter)
Short Term Debt = 91.0m USD (from shortTermDebt, last quarter)
Debt = 4.37b USD (from shortLongTermDebtTotal, last quarter) + Leases 248.0m
Net Debt = 3.70b USD (calculated: Debt 4.37b - CCE 671.0m)
Enterprise Value = 5.76b USD (2.06b + Debt 4.37b - CCE 671.0m)
Interest Coverage Ratio = -1.48 (Ebit TTM -404.0m / Interest Expense TTM 273.0m)
EV/FCF = 46.08x (Enterprise Value 5.76b / FCF TTM 125.0m)
FCF Yield = 2.17% (FCF TTM 125.0m / Enterprise Value 5.76b)
FCF Margin = 2.16% (FCF TTM 125.0m / Revenue TTM 5.80b)
Net Margin = -5.24% (Net Income TTM -304.0m / Revenue TTM 5.80b)
Gross Margin = 15.34% ((Revenue TTM 5.80b - Cost of Revenue TTM 4.91b) / Revenue TTM)
Gross Margin QoQ = 17.98% (prev 15.57%)
Tobins Q-Ratio = 0.81 (Enterprise Value 5.76b / Total Assets 7.15b)
Interest Expense / Debt = 6.25% (Interest Expense 273.0m / Debt 4.37b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -319.2m (EBIT -404.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.66 (Total Current Assets 3.09b / Total Current Liabilities 1.86b)
Debt / Equity = -89.14 (negative equity) (Debt 4.37b / totalStockholderEquity, last quarter -49.0m)
Debt / EBITDA = -43.49 (negative EBITDA) (Net Debt 3.70b / EBITDA -85.0m)
Debt / FCF = 29.58 (Net Debt 3.70b / FCF TTM 125.0m)
Total Stockholder Equity = 178.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.15% (Net Income -304.0m / Total Assets 7.15b)
RoE = -170.3% (Net Income TTM -304.0m / Total Stockholder Equity 178.5m)
RoCE = -10.06% (EBIT -404.0m / Capital Employed (Equity 178.5m + L.T.Debt 3.84b))
RoIC = -6.27% (negative operating profit) (NOPAT -319.2m / Invested Capital 5.09b)
WACC = 7.12% (E(2.06b)/V(6.43b) * Re(11.74%) + D(4.37b)/V(6.43b) * Rd(6.25%) * (1-Tc(0.21)))
Discount Rate = 11.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.13 | Cagr: 0.39%
[DCF] Terminal Value 75.44% ; FCFF base≈125.0m ; Y1≈125.5m ; Y5≈133.0m
[DCF] Fair Price = N/A (negative equity: EV 2.07b - Net Debt 3.70b = -1.63b; debt exceeds intrinsic value)
EPS Correlation: -93.27 | EPS CAGR: -36.04% | SUE: -0.09 | # QB: 0
Revenue Correlation: -69.26 | Revenue CAGR: -1.13% | SUE: -2.55 | # QB: -2
EPS current Quarter (2026-09-30): EPS=0.27 | Chg30d=-20.68% | Revisions=-73% | Analysts=8
EPS current Year (2026-12-31): EPS=1.01 | Chg30d=+14.92% | Revisions=-55% | GrowthEPS=+6.2% | GrowthRev=+2.0%
EPS next Year (2027-12-31): EPS=1.93 | Chg30d=-8.19% | Revisions=-73% | GrowthEPS=+91.1% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -81% (up=1, down=23)